Stocktoria
PROKIDNEY CORP. PROK
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-06-30
Chart by TradingView
1/9
Piotroski F — financial health
-41.28
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $893,000 | $76,000 | $0 | $0 | — |
| Operating income | -$165.0M | -$183.7M | -$151.5M | -$153.0M | -$55.1M |
| Net income | -$69.0M | -$61.2M | -$35.5M | — | -$55.1M |
| Operating cash flow | -$120.1M | -$126.4M | -$90.1M | -$77.1M | -$50.3M |
| Free cash flow | -$135.3M | -$155.9M | -$124.3M | -$78.9M | -$55.5M |
| Total assets | $335.6M | $441.1M | $420.6M | $518.0M | $40.3M |
| Total liabilities | $34.8M | $39.4M | $29.2M | $13.1M | $13.4M |
| Shareholders' equity | -$1.0B | -$995.0M | -$1.1B | -$1.1B | $26.9M |
| Ratios | |||||
| Operating margin | -18477.8% | -241678.9% | — | — | — |
| Net margin | -7725.2% | -80507.9% | — | — | — |
| FCF margin | -15152.6% | -205078.9% | — | — | — |
| Return on assets | -20.6% | -13.9% | -8.4% | — | -136.8% |
| Return on equity | 6.8% | 6.1% | 3.2% | — | -204.9% |
| Current ratio | 9.13 | 10.93 | 14.94 | 46.42 | 2.21 |
| Revenue growth | 1075.0% | — | — | — | — |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 1,250,794 | $2.2M |
| Point72 Asset Management, L.P. | 65,578 | $117,385 |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -41.28 (distress)
- Working capital / assets 0.745
- Retained earnings / assets -3.784
- EBIT / assets -0.492
- Equity / liabilities -29.073
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001850270 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.